Trexquant Investment LP Sells 74,350 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Trexquant Investment LP lowered its position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 47.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 80,842 shares of the company's stock after selling 74,350 shares during the quarter. Trexquant Investment LP owned approximately 0.11% of Kiniksa Pharmaceuticals worth $1,599,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in KNSA. FMR LLC lifted its stake in Kiniksa Pharmaceuticals by 36,925.0% in the 3rd quarter. FMR LLC now owns 696,810 shares of the company's stock valued at $17,413,000 after purchasing an additional 694,928 shares during the last quarter. Jane Street Group LLC raised its stake in Kiniksa Pharmaceuticals by 1,064.4% in the third quarter. Jane Street Group LLC now owns 345,092 shares of the company's stock valued at $8,624,000 after buying an additional 315,456 shares during the period. JPMorgan Chase & Co. lifted its position in shares of Kiniksa Pharmaceuticals by 138.9% in the fourth quarter. JPMorgan Chase & Co. now owns 477,800 shares of the company's stock valued at $9,451,000 after buying an additional 277,827 shares during the last quarter. Raymond James Financial Inc. bought a new position in shares of Kiniksa Pharmaceuticals during the 4th quarter worth approximately $3,955,000. Finally, Globeflex Capital L P increased its holdings in shares of Kiniksa Pharmaceuticals by 217.1% during the 4th quarter. Globeflex Capital L P now owns 88,596 shares of the company's stock worth $1,752,000 after acquiring an additional 60,656 shares during the last quarter. Institutional investors and hedge funds own 53.95% of the company's stock.

Kiniksa Pharmaceuticals Stock Performance

Shares of KNSA stock traded up $0.46 on Tuesday, hitting $21.15. The company's stock had a trading volume of 62,156 shares, compared to its average volume of 458,053. Kiniksa Pharmaceuticals, Ltd. has a fifty-two week low of $16.56 and a fifty-two week high of $28.15. The company has a market capitalization of $1.54 billion, a PE ratio of -151.31 and a beta of 0.31. The stock's 50 day moving average is $20.99 and its 200-day moving average is $21.57.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last announced its earnings results on Tuesday, February 25th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The business had revenue of $122.50 million for the quarter, compared to analyst estimates of $123.42 million. During the same quarter in the previous year, the company earned $0.35 EPS. The business's revenue for the quarter was up 46.9% on a year-over-year basis. On average, research analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current year.

Insider Buying and Selling at Kiniksa Pharmaceuticals

In related news, CAO Michael R. Megna sold 9,051 shares of the firm's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $22.45, for a total value of $203,194.95. Following the transaction, the chief accounting officer now owns 26,528 shares in the company, valued at approximately $595,553.60. This trade represents a 25.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Mark Ragosa sold 36,372 shares of the company's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $22.25, for a total transaction of $809,277.00. Following the sale, the chief financial officer now directly owns 22,958 shares of the company's stock, valued at $510,815.50. This represents a 61.30 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 79,766 shares of company stock valued at $1,756,375 in the last three months. Corporate insiders own 54.57% of the company's stock.

Wall Street Analyst Weigh In

KNSA has been the subject of a number of research analyst reports. Citigroup started coverage on shares of Kiniksa Pharmaceuticals in a research report on Thursday, March 13th. They set a "buy" rating and a $40.00 price objective for the company. Wedbush reaffirmed an "outperform" rating and set a $34.00 target price on shares of Kiniksa Pharmaceuticals in a report on Tuesday, February 25th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $37.17.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.